Midi Health Review: A Real Price List, and the Bill It Leaves Out

Two bills, and you need both. The medication: $355 for a four-week supply of injectable semaglutide at the 2.5 mg maintenance dose, or $375 for injectable tirzepatide at 10 mg — shipping and supplies included, no membership fee. The clinician: $250 for your first visit and $150 for each one after if you self-pay, or a specialist copay if you use insurance, which Midi says averages about $50. Read off joinmidi.com/glp1-pricing and joinmidi.com/pricing-insurance on August 9, 2026. Midi's own "as low as $164" is real, but it is the smallest sublingual dose and almost nobody stays there.

Because it is the bottom of two different ladders at once. It is the lowest dose — 0.075 mg — and it is the sublingual formulation rather than the injection most patients are prescribed. Midi publishes the whole ladder, which is what makes this checkable rather than a guess: injectable semaglutide is $165.90 through 0.5 mg, $270.90 through 1.5 mg, $340.00 at 1.75–2 mg and $355.00 at 2.5 mg. Semaglutide is a titration drug — you climb over months — so the starting price is a number you pass through, not one you live at. Doubling is the normal outcome here, not the worst case.

No, and this is the one thing Midi's otherwise excellent pricing page does not tell you. Visits are billed separately: $250 for the initial consultation and $150 for each continued-care visit if you are paying cash. Midi's help centre puts it plainly — "The visit price does not include the cost of labs or any prescription medications" — and the reverse is equally true, so the medication price does not include the visit. For a first four-week cycle that means $605 rather than $355, and every follow-up after that adds $150. It is not a hidden fee, exactly; it is a disclosed fee on a page you have to go looking for.

Midi does not say, which is the real gap in an otherwise transparent price list. The help centre explains only that refills "become available for purchase according to the recommended schedule of your prescription" and that "if you are out of refills you will be prompted to book a visit with your Midi clinician". Without a published interval you cannot compute your own annual cost before you sign up. The figures on this page therefore use the cheapest defensible reading — one initial visit and one renewal in a year, $400 spread across thirteen four-week cycles. If your clinician wants you quarterly, add $300 a year; if monthly during titration, considerably more.

At the semaglutide maintenance dose, thirteen supplies at $355 is $4,615 of medication, and with the minimal care allocation the all-in is $5,018. At the tirzepatide 10 mg dose it is $4,875 of medication and $5,278 all-in; at 15 mg, $5,642 and $6,045. The thirteen matters — Midi bills per four-week supply rather than per calendar month, which is thirteen purchases a year rather than twelve, and worth roughly one extra month of medication. To Midi's credit, it never calls a four-week supply a month, so this is arithmetic the site invites rather than conceals.

It is a genuine oddity and worth flagging before you buy. Across the whole pricing page — four tables, thirty-two dose rows — the word semaglutide appears zero times and tirzepatide zero times. The products are named "GLP-1 Injectable", "Dual-Action GLP-1/GIP Injectable" and their sublingual equivalents, which is a drug class being used as a product name. The molecules are identifiable anyway: the store URLs are /store/semaglutide and /store/tirzepatide, one page title reads "Compounded Tirzepatide and Weight Loss", and the dose ladders settle it — 0.1 to 2.5 mg is semaglutide's and nobody else's, and a compounded dual GLP-1/GIP agonist is tirzepatide by definition. But you should not have to reverse-engineer what you are being sold from a dose table.

Unverifiable, and it is not counted here. Midi's weight-management page says "We'll prescribe medications and build a microdosing program around your body's unique needs, if clinically appropriate. Weekly doses start at $34 for eligible patients." Four weeks of that is $136 — less than the $164.00 that is the cheapest of the thirty-two entries in Midi's own published table. There is no microdosing page (three plausible URLs all return 404), no four-week price for it anywhere, and no way to reconcile it with the price list. A per-week figure with no supply price behind it is a marketing number, and multiplying it out would be inventing a row.

For the doctor, yes anywhere — Midi's help centre says it is available in all 50 states, last updated May 2026. For the compounded medication it depends which pharmacy fills it, and Midi names both along with their limits: Precision Compounding Pharmacy ships everywhere except South Carolina and Arkansas, Belmar Pharmacy everywhere except Arkansas and Alabama. Arkansas is the only state neither will serve, so an Arkansas patient can have a Midi visit and a Midi prescription but cannot receive Midi's compounded GLP-1. South Carolina and Alabama each keep one pharmacy. This is disclosed only in the help centre, not on any pricing or product page.

Not to Midi. The live warning-letter index was queried on August 9, 2026 as "midi health", "joinmidi", "midi" and "midi inc", and every one returned nothing, with the result count matching the filtered count each time so nothing was hidden by paging. A positive control returned SkinnyRx's February 2026 letter in the same pass, so the absence is a finding rather than a broken query. Precision Compounding Pharmacy is also clean. Belmar is the one exception and deserves accuracy rather than alarm: a March 31, 2023 letter names Belmar Pharma Solutions as its corporate addressee, but the inspection it reports was of an affiliated Florida pharmacy, Drug Depot LLC dba APS Pharmacy, and FDA formally closed the matter out on October 30, 2023. A warning letter is a public regulatory communication, not a finding of illegal activity, and a closed-out one is a matter FDA considers resolved.

Assume not. Midi's Terms of Purchase are blunt: all fees are "non-cancellable and non-refundable" except where the terms say otherwise, and a written request to cancel an order before it ships is something "Midi may approve or deny in its discretion". That is standard for dispensed compounded prescriptions, but it interacts badly with the pricing structure — you can spend $250 on a visit and discover the clinician will not prescribe, or spend $355 on a four-week supply and stop after one injection because of side effects, and neither is refundable. The saving grace is that there is no subscription behind it: nothing renews, so the most you can lose is the order you placed.